Incyte 2012 Annual Report
to Stockholders
Jakafi® (ruxolitinib)
Prescribing Information

is a biopharmaceutical company focused on discovering, developing and commercializing proprietary small molecule drugs for oncology and inflammation.

Incyte Announces Positive Top-Line Results from Phase III Study of Ruxolitinib in Patients with Polycythemia Vera
Incyte Reports 2013 Fourth-Quarter and Year-End Financial Results; Provides 2014 Financial Guidance; Updates Shareholders on Key Clinical Programs
Incyte Announces Clinical Trial Collaboration with Merck to Evaluate Combination of Two Novel Immunotherapies
Jakafi® (ruxolitinib)
Connecting to Access, Reimbursement, Education and Support
To learn more, click here